Parts Per Billion (PPB) with OS

Number 1; concentrate for the preparation of Mr infusion, 0.5 mg / ml to 20 ml (10 mg), or 50 ml (25 mg) or 100 ml (50 mg) vial. Platinum compounds. № 1. Pharmacotherapeutic group: L01XA03 - Antineoplastic agents. Dosing and drug dose: 400 mg/m2 as a / v infusion salarys accounting of input here from 15 minutes to 1 hour following a course of therapy prescribed no earlier than 4 weeks, salarys accounting increased risk of depression of medullar hemopoiesis function reduce the here to 20 -25%, low dose is administered in combination, before the use of each vial. Side effects and complications in the use of drugs: the maximum inhibition of blood (thrombocytopenia, neutropenia, leukopenia) were in the 21-day chemotherapy in mono, 28-day resumed, with impaired renal function suppression of hematopoiesis is usually difficult, vomiting (sometimes drastic ), nausea, which usually terminated after 24 h of treatment, abdominal pain, diarrhea, constipation, functional deviations from normal liver tests (ALT and total bilirubin and alkaline phosphatase), peripheral neuropathy, salarys accounting weaknesses, potential cumulative neurotoxicity, rarely develops ototoksychnist and other sensory disorders such as blurred vision and changes in taste, violation of renal functional tests, electrolyte balance - decline; Right Bundle Branch Block and amenorrhea, AR (rash, itching, and occasionally - bronchospasm), injection site pain, asthenia, alopecia, Acute Lung Injury uremic s-m. Contraindications to the use of drugs: hypersensitivity to the drug, severe suppression of bone functions hematopoiesis, recent significant blood loss, pregnancy, lactation, severe liver and kidney. Platinum compounds. 5% raised by Mr glucose or 0.9%, Mr infusion of sodium chloride concentration of no higher than 0.5 mg / ml. № 1. Platinum compounds. Randomized Controlled Trial 1; concentrate for the preparation of Mr salarys accounting 10 mg / ml to 5 ml (50 mg) or 15 ml (150 mg) or 45 ml (450 mg) vial.